SCHEMBL21361600

SCHEMBL21361600

CC(C)N1CCc2cc(-c3ccccc3)ccc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.47
TMEM97 Q5BJF2 2/20 0.45
SIGMAR1 Q99720 2/20 0.45
CHRM2 P08172 1/20 0.45
HTR1A P08908 1/20 0.45
CHRM3 P20309 1/20 0.45
DRD4 P21917 1/20 0.45
ADRA1D P25100 1/20 0.45
HTR2C P28335 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
DRD3 P35462 1/20 0.45
HTR2B P41595 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HSD17B3 P37058 2/20 0.42
OGA O60502 1/20 0.40
ABHD6 Q9BV23 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12878742 0.81 CYP11B1 (0.43) HRH3SLC6A3OGACYP11B1CYP11B2
SCHEMBL12878738 0.81 HRH3 (0.41) HRH3ADRA1DADRA1AADRA1BOGA
SCHEMBL1083820 0.79 MAOA (0.57) HRH3DRD4DRD3OGAKDM4E
SCHEMBL30561536 0.79 MAOA (0.57) HRH3DRD4DRD3OGAKDM4E
SCHEMBL13499613 0.77 HRH3 (0.43) HRH3OGAKDM4EALDH1A1LMNA
SCHEMBL24616867 0.76 HSD17B3 (0.42) HRH3ADRA1DADRA1AADRA1BHSD17B3
SCHEMBL21361477 0.76 HTR2A (0.44) HRH3TMEM97SIGMAR1HTR2CHTR2B
SCHEMBL2741634 0.76 OGA (0.43) HRH3OGAKDM4EALDH1A1LMNA
SCHEMBL21361596 0.76 CARM1 (0.48) HRH3HTR2CHTR2BHSD17B3ABHD6
SCHEMBL15142196 0.76 DRD1 (0.54) HRH3DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G HRH3 4735/4885TMEM97 1269/4885SIGMAR1 2641/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G HRH3 4702/4885TMEM97 963/4885SIGMAR1 2378/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G HRH3 4736/4885TMEM97 916/4885SIGMAR1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.